Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. (CBAY) Stock Overview

Explore CymaBay Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CBAY●NASDAQ
HealthcareBiotechnology
$32.48
$0.010(0.03%)
U.S. Market is Open · 15:10

CymaBay Therapeutics, Inc. (CBAY)

Meyka AI Score

Z

Key Financials

Market Cap3.7B
P/E Ratio-32.81
EPS (TTM)$-0.99
ROE-0.64%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$78.28

CBAY Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, CymaBay Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CBAY on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $78.28 for the NASDAQ listing.

Key metrics behind CymaBay Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -32.81 and a market capitalization of 3.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CBAY on the NASDAQ.

Price Performance (NASDAQ: CBAY)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
0.03%
3-Month Change
32.57%
6-Month Change
138.65%
Year-to-Date (YTD) Change
36.99%
1-Year Change
215.95%
3-Year Change
678.90%
5-Year Change
169.54%
All-Time (Max) Change
260.89%

Contact Information

https://www.gilead.com
510 293 8800
7575 Gateway Boulevard, Newark, CA, 94560

Company Facts

1,010 Employees
IPO DateFeb 3, 2014
CountryUS

Frequently Asked Questions